Prognostic implications of HER2NEU-low in metastatic breast cancer.

ABSTRACT:

Introduction

We explored characteristics and clinical outcomes of HER2-negative and HER2-low metastatic breast cancers using real-world data.

Methods

We queried the National Cancer Database to identify MBC patients that were HER2-low or HER2-negative per immunohistochemical staining. A binomial regression analysis identified demographic and clinical correlates of each subtype. A Cox multivariable regression analysis (MVA) and propensity-match analysis were performed to identify correlates of survival.

Results

Excluding missing data, 24,636 MBC patients diagnosed between 2008 and 2015 were identified; 27.9% were HER2-negative and 72.1% were HER2-low. There were no relevant demographic differences between the groups. HER2-low tumors were half as likely to have concomita

SUBMITTER: Neubauer Z 

PROVIDER: S-EPMC10839127 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature